Press Release

Statement on Introduction of the Innovation Act, H.R. 9

PhRMA February 10, 2015

Washington, D.C. (February 5, 2015) — The following statement is provided by Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO, John J. Castellani:

“We thank Chairman Goodlatte for his leadership in the effort to curb abusive practices that can arise in patent litigation and enforcement.  We look forward to reviewing this proposal and working with Congress to ensure legislation addressing patent litigation is not harmful to the patent system.

“Strong intellectual property protections are crucially important to the biopharmaceutical industry and the patients we serve.  As such, PhRMA looks forward to working with Chairman Goodlatte and the Judiciary Committee to ensure these abusive practices are addressed without degrading the ability of legitimate patent holders to protect and enforce their legitimate intellectual property rights.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $550 billion in the search for new treatments and cures, including an estimated $51.1 billion in 2013 alone. 

Find PhRMA Online:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health emergencies, visit